Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2012

View Archived Issues

Amgen presents novel TRPM8 channel antagonist

Novel antidiabetic drug Subetta evaluated in animal model

Novel deuterated analogues of mibefradil show reduced propensity for CYP3A4-mediated interactions

Studies support the use of tofogliflozin in patients with renal impairment

BioCryst Pharmaceuticals enters merger agreement

Starpharma completes recruitment in phase III VivaGel trials

Biogen Idec notified of PDUFA date extension

FDA accepts quadrivalent influenza vaccine sBLA for review

First use of CardioCel tissue patch to repair congenital heart defects

Progen Pharmaceuticals reports phase II data for PI-88 in melanoma

ProNoxis researchers synthesize new ROS production enhancers

Advinus Therapeutics presents new JAK inhibitors

Researchers describe activity of TAC-302

Trevena divulges new opioid receptor ligands

FDA committee votes to recommend approval of Kynamro

New IL-7A proteins prepared at the University of Central Florida

Phase II and III studies of bardoxolone methyl suspended

Hyundai Pharmaceutical patents new 11-beta-HSD1 inhibitors

Japanese Foundation for Cancer Research presents new antibodies

Quantum Genomics reports promising results from phase Ia trial of new antihypertensive agent

Curis achieves first milestones in CUDC-907 development

Ipsen to conduct phase II study of tasquinimod in multiple tumor types

EMA committee issues opinion on Qsiva

Pfenex receives NIH contract to develop dry formulation of rPA-based anthrax vaccine

Redx Pharma receives support to launch center for antiviral and antibacterial drugs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.